People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.
SGLT2 inhibitors reduce the risk for adverse outcomes in a broad range of patients with heart failure, suggest findings from a meta-analysis of five randomized placebo-controlled trials.
The only notable short-term differences in the effects of sotagliflozin and empagliflozin occur in glucose metabolism after breakfast, show findings from a randomized trial.